Dr. Christian Roesky

Dr. Christian Roesky is Chief Executive Officer Novaliq since 2016, a private biopharmaceutical company focusing on the development of first and best-in-class ocular therapeutics. Novaliq developed EyeSol®, a novel drug category of water-free topical eye medicines. The R&D pipeline provides multiple opportunities in ophthalmology and retina therapies. Two EyeSol®-based dry eye disease drug therapies, Miebo™ and Vevye™, were recently FDA-approved. 

Previously, he was General Manager for Bausch + Lomb in Europe; Commercial Director Central Europe at Abbott Diagnostics Division; and General Manager Alcon Germany & Austria at Novartis. Prior to his executive assignments, Dr. Roesky worked as Marketing Manager EMEA for Alcon in the USA, Spain and Switzerland. He studied chemistry in Bonn and Freiberg (both Germany) and was awarded his Ph.D. with honors from the Technical University of Freiberg. Dr. Roesky serves as a board director at Betaliq Inc and Dermaliq Therapeutics Inc. He is vice chairman and board member of the Bundesverband der Pharmazeutischen Industrie (BPI), the trade organization of the German pharmaceutical industry.